{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:40:45Z","timestamp":1793320845717,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cpcardiol.2022.101342","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T02:20:44Z","timestamp":1659234044000},"page":"101342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Lipid Lowering Therapy: An Era Beyond Statins"],"prefix":"10.1016","volume":"47","author":[{"given":"Toufik","family":"Abdul-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Awais","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano Cantu","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wireko Andrew","family":"Awuah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannel","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heloisa","family":"de Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo Andr\u00e9s Avenda\u00f1o","family":"Capriles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebahat","family":"Ulusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzaib","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Corriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana C.","family":"Mares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4972-9073","authenticated-orcid":false,"given":"Adrija","family":"Hajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhrubajyoti","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0001","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11883-014-0414-4","article-title":"Beyond statins: new lipid lowering strategies to reduce cardiovascular risk","volume":"16","author":"Noto","year":"2014","journal-title":"Curr Atheroscler Rep"},{"issue":"16","key":"10.1016\/j.cpcardiol.2022.101342_bib0002","doi-asserted-by":"crossref","first-page":"E1189","DOI":"10.1503\/cmaj.101280","article-title":"Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis","volume":"183","author":"Tonelli","year":"2011","journal-title":"Cmaj"},{"issue":"5009","key":"10.1016\/j.cpcardiol.2022.101342_bib0003","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1126\/science.252.5009.1080","article-title":"Are prescription drug prices high?","volume":"252","author":"Vagelos","year":"1991","journal-title":"Science"},{"issue":"5519","key":"10.1016\/j.cpcardiol.2022.101342_bib0004","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101342_bib0006","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic Interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0007","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.ATV.15.5.678","article-title":"Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor","volume":"15","author":"Nawrocki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10170","key":"10.1016\/j.cpcardiol.2022.101342_bib0008","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Collaboration","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009217.pub2","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"10.1016\/j.cpcardiol.2022.101342_bib0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0011","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin Safety and Associated adverse events: a scientific statement from the American heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"10.1016\/j.cpcardiol.2022.101342_bib0012","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0013","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/VHRM.S3390","article-title":"Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing","volume":"4","author":"Farnier","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0014","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-6-5","article-title":"Bempedoic acid for the treatment of dyslipidemia","volume":"9","author":"Marrs","year":"2020","journal-title":"Drugs Context"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0015","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11883-020-00836-w","article-title":"Efficacy and Safety of Volanesorsen (ISIS 304801): the evidence from Phase 2 and 3 clinical trials","volume":"22","author":"Fogacci","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0016","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2217\/clp.10.73","article-title":"Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies","volume":"5","author":"Kassim","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0017","series-title":"Endotext [Internet]","article-title":"Introduction to Lipids and Lipoproteins. [Updated 2021 Jan 19]","author":"Feingold","year":"2000"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-nutr-071714-034338","article-title":"new insights into the regulation of chylomicron production","volume":"35","author":"Dash","year":"2015","journal-title":"Annu Rev Nutr"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101342_bib0019","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00041433-199405030-00007","article-title":"Metabolism of VLDL and LDL subclasses","volume":"5","author":"Griffin","year":"1994","journal-title":"Curr Opin Lipidol"},{"issue":"22","key":"10.1016\/j.cpcardiol.2022.101342_bib0020","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101342_bib0021","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2003.11.006","article-title":"Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms","volume":"40","author":"Chiang","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0022","series-title":"Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"issue":"3-4","key":"10.1016\/j.cpcardiol.2022.101342_bib0023","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.progpolymsci.2012.09.004","article-title":"Polymeric bile acid sequestrants\u2014Synthesis using conventional methods and new approaches based on \u201ccontrolled\u201d\/living radical polymerization","volume":"38","author":"Mendon\u00e7a","year":"2013","journal-title":"Progress in Polymer Science"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101342_bib0024","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101342_bib0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00007611-197503000-00011","article-title":"Colestipol hydrochloride, a new hypolipidemic drug: a two-year study","volume":"68","author":"Cooper","year":"1975","journal-title":"South Med J"},{"issue":"10","key":"10.1016\/j.cpcardiol.2022.101342_bib0026","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4065\/76.10.971","article-title":"Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial","volume":"76","author":"Insull","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101342_bib0027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11739-011-0653-0","article-title":"Use and indications of cholestyramine and bile acid sequestrants","volume":"8","author":"Scaldaferri","year":"2013","journal-title":"Intern Emerg Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0028","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/j.1552-4604.1990.tb03447.x","article-title":"Bile acid sequestrants","volume":"30","author":"Ast","year":"1990","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0029","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157016108785909698","article-title":"Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome","volume":"6","author":"Yamaoka-Tojo","year":"2008","journal-title":"Curr Vasc Pharmacol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/dmd.30.4.430","article-title":"Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects","volume":"30","author":"Patrick","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0031","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40256-020-00421-1","article-title":"Rosuvastatin\/Ezetimibe: a review in hypercholesterolemia","volume":"20","author":"Lamb","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"Suppl A","key":"10.1016\/j.cpcardiol.2022.101342_bib0032","first-page":"13a","article-title":"The pharmacokinetics of ezetimibe","volume":"10","author":"Simard","year":"2003","journal-title":"Can J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0033","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"1-3","key":"10.1016\/j.cpcardiol.2022.101342_bib0034","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2010.02.003","article-title":"Pleiotropic effects of ezetimibe: do they really exist?","volume":"633","author":"Kalogirou","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2022.101342_bib0035","first-page":"53","article-title":"Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties","volume":"33","author":"Masana Mar\u00edn","year":"2021","journal-title":"Clin Investig Arterioscler"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0036","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","article-title":"Role of bempedoic acid in clinical practice","volume":"35","author":"Ballantyne","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0037","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"19","key":"10.1016\/j.cpcardiol.2022.101342_bib0038","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0039","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5551\/jat1994.3.81","article-title":"Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects","volume":"3","author":"Auwerx","year":"1996","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","author":"Miller","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0041","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11883-009-0051-5","article-title":"Fibrate therapy and renal function","volume":"11","author":"Sica","year":"2009","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0042","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MOL.0b013e328332e9ef","article-title":"Combination therapy of statins and fibrates in the management of cardiovascular risk","volume":"20","author":"Fi\u00e9vet","year":"2009","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0043","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/j.1875-9114.1988.tb04085.x","article-title":"Nicotinic acid: a review of its clinical use in the treatment of lipid disorders","volume":"8","author":"Figge","year":"1988","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0044","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J Intern Med"},{"issue":"8a","key":"10.1016\/j.cpcardiol.2022.101342_bib0046","doi-asserted-by":"crossref","first-page":"20b","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0047","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosissup.2012.10.036","article-title":"Nicotinic acid as a lipid-modifying drug\u2013a review","volume":"14","author":"Julius","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0048","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0955-2863(02)00284-X","article-title":"Niacin and cholesterol: role in cardiovascular disease (review)","volume":"14","author":"Ganji","year":"2003","journal-title":"J Nutr Biochem"},{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101342_bib0049","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jama.1996.03540070040028","article-title":"Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study","volume":"276","author":"Bostom","year":"1996","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.cpcardiol.2022.101342_bib0050","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of extended-release nicotinic acid on apolipoprotein(a) Kinetics in hypertriglyceridemic patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"11","key":"10.1016\/j.cpcardiol.2022.101342_bib0051","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0052","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1515\/acph-2016-0043","article-title":"Pleiotropic effects of niacin: current possibilities for its clinical use","volume":"66","author":"Zeman","year":"2016","journal-title":"Acta Pharm"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0053","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.atherosclerosis.2008.04.044","article-title":"Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells","volume":"202","author":"Ganji","year":"2009","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0054","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2006.04.011","article-title":"Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease","volume":"98","author":"Kuvin","year":"2006","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101342_bib0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11883-017-0697-3","article-title":"ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen","volume":"19","author":"Rocha","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0056","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/DDDT.S224771","article-title":"Volanesorsen in the treatment of familial chylomicronemia syndrome or hypertriglyceridaemia: design, development and place in therapy","volume":"14","author":"Esan","year":"2020","journal-title":"Drug Des Devel Ther."},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0057","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101342_bib0058","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1358\/dot.2018.54.12.2899384","article-title":"Volanesorsen for treatment of patients with familial chylomicronemia syndrome","volume":"54","author":"Warden","year":"2018","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0059","first-page":"43","article-title":"PCSK9 inhibitors in the current management of atherosclerosis","volume":"87","author":"Whayne","year":"2017","journal-title":"Arch Cardiol Mex"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101342_bib0060","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14779072.2017.1409115","article-title":"Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review","volume":"15","author":"Farnier","year":"2017","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101342_bib0061","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 Inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0062","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","article-title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program","volume":"278","author":"Farnier","year":"2018","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101342_bib0063","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/17425255.2020.1828343","article-title":"An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity","volume":"16","author":"Mo\u015fteoru","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0064","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-018-0718-x","article-title":"Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitorsfrom molecular biology to clinical translation","volume":"20","author":"Karagiannis","year":"2018","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1253\/circj.CJ-18-0442","article-title":"ANGPTL3 inhibitors - their role in cardiovascular disease through regulation of lipid metabolism","volume":"83","author":"Geladari","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0066","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-8-3","article-title":"New and emerging lipid-modifying drugs to lower LDL cholesterol","volume":"10","author":"Kosmas","year":"2021","journal-title":"Drugs Context"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101342_bib0067","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","article-title":"New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein b: JACC focus seminar 1\/4","volume":"77","author":"Nurmohamed","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101342_bib0068","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11883-021-00972-x","article-title":"Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9 and ANGPTL3 inhibitors","volume":"23","author":"Pirillo","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"10.1016\/j.cpcardiol.2022.101342_bib0069","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/1061186X.2019.1566342","article-title":"ANGPTL3: a novel biomarker and promising therapeutic target","volume":"27","author":"Jiang","year":"2019","journal-title":"J Drug Target"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101342_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/diseases6030063","article-title":"Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia","volume":"6","author":"Kosmas","year":"2018","journal-title":"Diseases"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0071","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol Mol Biol Rev"},{"issue":"15","key":"10.1016\/j.cpcardiol.2022.101342_bib0072","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2022.101342_bib0073","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2022.101342_bib0074","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0075","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and Disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9-a narrative review","volume":"2022","author":"Mer\u0107ep","year":"2022","journal-title":"cardiovasc ther"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0076","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"40","key":"10.1016\/j.cpcardiol.2022.101342_bib0077","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0078","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","article-title":"ANGPTL3 as therapeutic target","volume":"32","author":"Kersten","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0079","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12944-021-01589-4","article-title":"Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study","volume":"20","author":"Foss-Freitas","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0081","first-page":"119","article-title":"Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia","volume":"39","author":"Wong","year":"2014","journal-title":"P t"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0082","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0083","doi-asserted-by":"crossref","first-page":"13","DOI":"10.31083\/j.rcm.2018.01.890","article-title":"Contribution of ApoCIII to diabetic dyslipidemia and treatment with volanesorsen","volume":"19","author":"Zhang","year":"2018","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0084","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0085","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40265-014-0339-9","article-title":"Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0086","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14712598.2013.738663","article-title":"Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency","volume":"13","author":"Wierzbicki","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101342_bib0087","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"R1","key":"10.1016\/j.cpcardiol.2022.101342_bib0088","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1093\/hmg\/ddz132","article-title":"Recent advances in novel therapies for lipid disorders","volume":"28","author":"Tirronen","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0089","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/humc.2017.014","article-title":"Non-clinical study examining AAV8.TBG.hLDLR vector-associated toxicity in chow-fed wild-Type and LDLR(+\/-) Rhesus Macaques","volume":"28","author":"Greig","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"10","key":"10.1016\/j.cpcardiol.2022.101342_bib0090","doi-asserted-by":"crossref","first-page":"e13424","DOI":"10.1371\/journal.pone.0013424","article-title":"Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis","volume":"5","author":"Kassim","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0091","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","article-title":"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors","volume":"9","author":"Thakore","year":"2018","journal-title":"Nat Commun"},{"issue":"7859","key":"10.1016\/j.cpcardiol.2022.101342_bib0092","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0093","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","article-title":"Molecular mechanisms of long noncoding RNAs","volume":"43","author":"Wang","year":"2011","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0094","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","volume":"141","author":"Lu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"10.1016\/j.cpcardiol.2022.101342_bib0095","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.111.030932","article-title":"Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure","volume":"124","author":"Montgomery","year":"2011","journal-title":"Circulation"},{"issue":"7068","key":"10.1016\/j.cpcardiol.2022.101342_bib0096","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with 'antagomirs'","volume":"438","author":"Kr\u00fctzfeldt","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0097","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCRESAHA.111.244442","article-title":"Inhibition of miR-15 protects against cardiac ischemic injury","volume":"110","author":"Hullinger","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0098","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/CIRCULATIONAHA.117.029002","article-title":"Long noncoding RNA facilitated gene therapy reduces atherosclerosis in a murine model of familial hypercholesterolemia","volume":"136","author":"Tontonoz","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0099","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41419-019-1409-4","article-title":"LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation","volume":"10","author":"Ye","year":"2019","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/10717544.2019.1628116","article-title":"Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K\/Akt signaling pathway","volume":"26","author":"Sun","year":"2019","journal-title":"Drug Deliv"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0101","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbrc.2018.03.127","article-title":"Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt\/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis","volume":"499","author":"Zhang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lfs.2018.04.028","article-title":"Long noncoding RNA lncARSR promotes hepatic cholesterol biosynthesis via modulating Akt\/SREBP-2\/HMGCR pathway","volume":"203","author":"Huang","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0103","series-title":"Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0104","first-page":"89","article-title":"Efficacy, Safety and protective effects of lipid lowering drugs in patients with diabetes","volume":"4","author":"Htira","year":"2022","journal-title":"Euro J Med Health Sci"},{"issue":"25","key":"10.1016\/j.cpcardiol.2022.101342_bib0105","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2022.101342_bib0106","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016262","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Di Minno","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0107","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.3390\/ijms22063144","article-title":"Pleiotropic effects of PCSK-9 inhibitors","volume":"22","author":"Basiak","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0108","first-page":"28","article-title":"Alirocumab (Praluent): First in the New class of PCSK9 inhibitors","volume":"41","author":"Manniello","year":"2016","journal-title":"P & T: a peer-reviewed journal for formulary management"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0109","article-title":"Evinacumab - The new kid on the block. Is it important for cardiovascular prevention?","volume":"11","author":"Surma","year":"2021","journal-title":"Int J Cardiol Cardiovascular Risk Prevention"},{"issue":"8","key":"10.1016\/j.cpcardiol.2022.101342_bib0110","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101342_bib0111","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101342_bib0112","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-0038-1676863","article-title":"PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention","volume":"119","author":"Paciullo","year":"2019","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.cpcardiol.2022.101342_bib0113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11883-021-00938-z","article-title":"Novel RNAi-based therapies for atherosclerosis","volume":"23","author":"Ruotsalainen","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/VHRM.S191965","article-title":"Mipomersen in familial hypercholesterolemia: an update on health-related quality of life and patient-reported outcomes","volume":"18","author":"Chambergo-Michilot","year":"2022","journal-title":"Vasc Health Risk Manag"},{"issue":"23","key":"10.1016\/j.cpcardiol.2022.101342_bib0115","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2022.101342_bib0116","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","article-title":"Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70","volume":"145","author":"Bergmark","year":"2022","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101342_bib0117","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.cpcardiol.2022.101342_bib0118","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.freeradbiomed.2013.07.014","article-title":"MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases","volume":"64","author":"Aranda","year":"2013","journal-title":"Free Radic Biol Med"},{"issue":"6472","key":"10.1016\/j.cpcardiol.2022.101342_bib0119","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav1741","article-title":"The biochemical basis of microRNA targeting efficacy","volume":"366","author":"McGeary","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101342_bib0120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/infdis\/jiw095","article-title":"Myocardial infarction-associated transcript, a long noncoding rna, is overexpressed during dilated cardiomyopathy due to chronic chagas disease","volume":"214","author":"Frade","year":"2016","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0121","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.apsb.2020.10.001","article-title":"Long non-coding RNAs: from disease code to drug role","volume":"11","author":"Chen","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101342_bib0122","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.gene.2015.12.032","article-title":"LncRNA MIAT: myocardial infarction associated and more","volume":"578","author":"Liao","year":"2016","journal-title":"Gene"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:58:21Z","timestamp":1758938301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622002390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":122,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0146280622002390"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101342","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid Lowering Therapy: An Era Beyond Statins","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101342"}}